quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·29d
PRRelease
Quantum Biopharma Ltd. logo

Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

QNTM· Quantum Biopharma Ltd.
Health Care
Original source

Companies

  • QNTM
    Quantum Biopharma Ltd.
    Health Care

Related

  • SEC2d
    SEC Form 6-K filed by Quantum Biopharma Ltd.
  • PR2d
    Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
  • SEC22d
    SEC Form 6-K filed by Quantum Biopharma Ltd.
  • PR22d
    Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
  • SEC23d
    SEC Form 6-K filed by Quantum Biopharma Ltd.
  • SEC25d
    SEC Form 6-K filed by Quantum Biopharma Ltd.
  • PR27d
    Quantum Biopharma Provides Corporate Update
  • SEC28d
    SEC Form 6-K filed by Quantum Biopharma Ltd.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022